Acromegaly is a rare endocrine disease generally caused by a pituitary adenoma, which is a non-cancerous tumor in the pituitary that secretes growth hormone. The PATHFNDR-2 study is evaluating ...

Affected populations: Acromegaly is estimated to affect approximately 50 to 70 people out of every million. However, the true figure may be higher, as the symptoms develop slowly and thus may go ...

The Acromegaly Consensus Group considered many of the advances that have occurred in the management of acromegaly over the past 10 years. First, the growth hormone receptor antagonist pegvisomant ...

ProBioGen and Marea Therapeutics Inc. have successfully completed a sprint project to deliver clinical material for MAR002.

Biochemical control of acromegaly in noncured patients is usually defined as serum growth hormone (GH) levels <2.0 µg/l, plus normal-for-age serum levels of insulin-like growth factor I (IGF-I).

The partnership focused on an integrated and accelerated chemistry, manufacturing, and controls (CMC) program for MAR002, Marea's investigational anti-growth hormone receptor (GHR) antibody for the ...